title: Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis.
abstract: Pertussis is a highly contagious respiratory illness caused by the bacterial pathogen Bordetella pertussis. Pertussis rates in the United States have escalated since the 1990s and reached a 50-year high of 48,000 cases in 2012. While this pertussis resurgence is not completely understood, we previously showed that the current acellular pertussis vaccines do not prevent colonization or transmission following challenge. In contrast, a whole-cell pertussis vaccine accelerated the rate of clearance compared to rates in unvaccinated animals and animals treated with the acellular vaccine. In order to understand if these results are generalizable, we used our baboon model to compare immunity from whole-cell vaccines from three different manufacturers that are approved outside the United States. We found that, compared to clearance rates with no vaccine and with an acellular pertussis vaccine, immunization with any of the three whole-cell vaccines significantly accelerated the clearance of B. pertussis following challenge. Whole-cell vaccination also significantly reduced the total nasopharyngeal B. pertussis burden, suggesting that these vaccines reduce the opportunity for pertussis transmission. Meanwhile, there was no difference in either the duration or in B. pertussis burden between unvaccinated and acellular-pertussis-vaccinated animals, while previously infected animals were not colonized following reinfection. We also determined that transcription of the gene encoding interleukin-17 (IL-17) was increased in whole-cell-vaccinated and previously infected animals but not in acellular-pertussis-vaccinated animals following challenge. Together with our previous findings, these data are consistent with a role for Th17 responses in the clearance of B. pertussis infection.
authors.affiliation: Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
authors.forename: Jason M
authors.initials: JM
authors.lastname: Warfel
authors.affiliation: Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
authors.forename: Lindsey I
authors.initials: LI
authors.lastname: Zimmerman
authors.affiliation: Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA tod.merkel@fda.hhs.gov.
authors.forename: Tod J
authors.initials: TJ
authors.lastname: Merkel
mesh_terms: D000818:Animals; D058491:Bacterial Load; D001886:Bordetella pertussis / Q000276:immunology; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D020381:Interleukin-17 / Q000235:genetics; D009305:Nasopharynx / Q000382:microbiology; D010215:Papio; D010567:Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology* / Q000592:standards; D014158:Transcription, Genetic; D014481:United States; D022282:Vaccines, Acellular / Q000008:administration & dosage / Q000276:immunology / Q000592:standards; D014917:Whooping Cough / Q000276:immunology* / Q000635:transmission
chemical_list: D015721:Diphtheria-Tetanus-Pertussis Vaccine; D020381:Interleukin-17; D010567:Pertussis Vaccine; D022282:Vaccines, Acellular